Targeted Cancer Therapy and Mechanisms of Resistance
Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called “oncogene addiction”. According to this concept, protein kinases have been identified as promising molecular targets for cancer thera...
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Matèries: | |
| Accés en línia: | ONIX_20220224_9783036528564_33 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869517301481472000 |
|---|---|
| collection | Directory of Open Access Books |
| description | Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called “oncogene addiction”. According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs. |
| format | Online |
| id | doab-20.500.12854ir-78735 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-787352024-03-28T03:33:17Z Targeted Cancer Therapy and Mechanisms of Resistance De Falco, Valentina 3D spheroids photothermy gold nanoparticles doxorubicin resistance colorectal cancer cellular prion protein PrPC PRNP cancer cancer stem cell targeted cancer therapy brain metastases treatment non-small cell lung carcinoma EGFR ALK immunotherapy HDAC6 bortezomib-resistance HDAC6-selective inhibitor bortezomib carfilzomib multiple myeloma LMP2 combination therapy colorectal cancer cells drug resistance 5-Fluorouracil thymidylate synthase exome sequencing CD47 immune activation pro-tumoral macrophages breast cancer polo-like kinase 1 (PLK1) pyrazole quantitative structure-activity relationship hybridization ovarian cancer cisplatin cisplatin resistance PARPi niraparib Twist lethality AF4 cell culture FGFR2 HOXA9 MLL-AF4 nucleus target therapy t(4 11) leukemia radiation-resistant cell death ERK EMT cancer stem cells (CSCs) PD98059 PARP inhibitors PARP inhibitor resistance signal transduction networks pathways event-free survival biomarkers WNT pathway targeted therapy Wee1 kinase cell cycle tumor resistance lenvatinib sorafenib-resistant hepatocellular carcinoma FGFR4 autophagy microRNA thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called “oncogene addiction”. According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs. 2022-02-24T10:34:40Z 2022-02-24T10:34:40Z 2022 book ONIX_20220224_9783036528564_33 9783036528564 9783036528571 https://directory.doabooks.org/handle/20.500.12854/78735 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4826 https://mdpi.com/books/pdfview/book/4826 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2856-4 10.3390/books978-3-0365-2856-4 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036528564 9783036528571 280 Basel open access |
| spellingShingle | 3D spheroids photothermy gold nanoparticles doxorubicin resistance colorectal cancer cellular prion protein PrPC PRNP cancer cancer stem cell targeted cancer therapy brain metastases treatment non-small cell lung carcinoma EGFR ALK immunotherapy HDAC6 bortezomib-resistance HDAC6-selective inhibitor bortezomib carfilzomib multiple myeloma LMP2 combination therapy colorectal cancer cells drug resistance 5-Fluorouracil thymidylate synthase exome sequencing CD47 immune activation pro-tumoral macrophages breast cancer polo-like kinase 1 (PLK1) pyrazole quantitative structure-activity relationship hybridization ovarian cancer cisplatin cisplatin resistance PARPi niraparib Twist lethality AF4 cell culture FGFR2 HOXA9 MLL-AF4 nucleus target therapy t(4 11) leukemia radiation-resistant cell death ERK EMT cancer stem cells (CSCs) PD98059 PARP inhibitors PARP inhibitor resistance signal transduction networks pathways event-free survival biomarkers WNT pathway targeted therapy Wee1 kinase cell cycle tumor resistance lenvatinib sorafenib-resistant hepatocellular carcinoma FGFR4 autophagy microRNA thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Targeted Cancer Therapy and Mechanisms of Resistance |
| title | Targeted Cancer Therapy and Mechanisms of Resistance |
| title_full | Targeted Cancer Therapy and Mechanisms of Resistance |
| title_fullStr | Targeted Cancer Therapy and Mechanisms of Resistance |
| title_full_unstemmed | Targeted Cancer Therapy and Mechanisms of Resistance |
| title_short | Targeted Cancer Therapy and Mechanisms of Resistance |
| title_sort | targeted cancer therapy and mechanisms of resistance |
| topic | 3D spheroids photothermy gold nanoparticles doxorubicin resistance colorectal cancer cellular prion protein PrPC PRNP cancer cancer stem cell targeted cancer therapy brain metastases treatment non-small cell lung carcinoma EGFR ALK immunotherapy HDAC6 bortezomib-resistance HDAC6-selective inhibitor bortezomib carfilzomib multiple myeloma LMP2 combination therapy colorectal cancer cells drug resistance 5-Fluorouracil thymidylate synthase exome sequencing CD47 immune activation pro-tumoral macrophages breast cancer polo-like kinase 1 (PLK1) pyrazole quantitative structure-activity relationship hybridization ovarian cancer cisplatin cisplatin resistance PARPi niraparib Twist lethality AF4 cell culture FGFR2 HOXA9 MLL-AF4 nucleus target therapy t(4 11) leukemia radiation-resistant cell death ERK EMT cancer stem cells (CSCs) PD98059 PARP inhibitors PARP inhibitor resistance signal transduction networks pathways event-free survival biomarkers WNT pathway targeted therapy Wee1 kinase cell cycle tumor resistance lenvatinib sorafenib-resistant hepatocellular carcinoma FGFR4 autophagy microRNA thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | 3D spheroids photothermy gold nanoparticles doxorubicin resistance colorectal cancer cellular prion protein PrPC PRNP cancer cancer stem cell targeted cancer therapy brain metastases treatment non-small cell lung carcinoma EGFR ALK immunotherapy HDAC6 bortezomib-resistance HDAC6-selective inhibitor bortezomib carfilzomib multiple myeloma LMP2 combination therapy colorectal cancer cells drug resistance 5-Fluorouracil thymidylate synthase exome sequencing CD47 immune activation pro-tumoral macrophages breast cancer polo-like kinase 1 (PLK1) pyrazole quantitative structure-activity relationship hybridization ovarian cancer cisplatin cisplatin resistance PARPi niraparib Twist lethality AF4 cell culture FGFR2 HOXA9 MLL-AF4 nucleus target therapy t(4 11) leukemia radiation-resistant cell death ERK EMT cancer stem cells (CSCs) PD98059 PARP inhibitors PARP inhibitor resistance signal transduction networks pathways event-free survival biomarkers WNT pathway targeted therapy Wee1 kinase cell cycle tumor resistance lenvatinib sorafenib-resistant hepatocellular carcinoma FGFR4 autophagy microRNA thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | ONIX_20220224_9783036528564_33 |